|
|||||
|
|

Digital medical services platform Teladoc Health (NYSE:TDOC) beat Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.6% year on year to $631.9 million. The company expects next quarter’s revenue to be around $625 million, close to analysts’ estimates. Its GAAP loss of $0.19 per share was 27.8% above analysts’ consensus estimates.
Is now the time to buy TDOC? Find out in our full research report (it’s free).
Teladoc’s second quarter results reflected a mix of headwinds and operational progress, with the company’s revenue and adjusted EBITDA exceeding Wall Street expectations but overall sales declining year-over-year. Management attributed the performance to ongoing softness in BetterHelp’s U.S. cash pay business, partially offset by growth in Integrated Care and international markets. CEO Charles Divita noted continued traction with recently launched offerings and emphasized, “We’re in a stronger position to execute in an evolving market.” The market’s modestly negative reaction followed cautious commentary on consumer sentiment and the competitive landscape in virtual mental health.
Looking forward, Teladoc’s guidance is shaped by a continued shift to insurance reimbursement models in BetterHelp, ongoing product innovation, and cost containment efforts. Management believes that expanding insurance coverage for BetterHelp users and rolling out new features across chronic care programs will be critical to restoring growth. CFO Mala Murthy cautioned that insurance margins will be lower than historical cash pay levels but expects higher conversion rates to support scale. Teladoc plans to maintain a methodical rollout of insurance and invest in operational capabilities, with ongoing updates planned as scaling progresses.
Management credited product innovation, international expansion, and operational efficiency as primary factors behind the quarter’s results, while acknowledging persistent challenges in the U.S. consumer mental health market.
Teladoc’s outlook is shaped by its transition to insurance models, ongoing product enhancements, and a focus on cost management as it addresses competitive and macroeconomic headwinds.
In future quarters, the StockStory team will monitor (1) the pace and geographic expansion of BetterHelp’s insurance coverage, including therapist recruitment and payer partnerships; (2) adoption rates and engagement for newly launched chronic care and mental health features; and (3) sustained growth in international markets, particularly as localized offerings roll out. Execution on cost management and supply chain adjustments in response to tariffs will also be closely tracked.
Teladoc currently trades at $6.83, down from $7.52 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| 12 hours | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-28 | |
| Oct-28 | |
| Oct-27 | |
| Oct-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite